tesamorelin + CJC-1295 + ipamorelin vs tesa+ipa blend

updated September 11, 2026

tesamorelin + CJC-1295 + ipamorelin (tier F) vs tesa+ipa blend (tier A): what each is, why each got its grade, half-life and source counts side by side.

tesamorelin + CJC-1295 + ipamorelin · tier F

a three-peptide GH-axis blend with no located direct study, whose CJC variant, component forms, and ratio must be known before even its duration can be described.

tier rationale

F-tier applies while formulation identity is unresolved and no fixed-blend safety study is located. The same CJC label can refer to molecules whose duration differs by orders of magnitude, tesamorelin's approval does not transfer to a combination, and no located animal or human study tests all three together. Exact verified forms and ratios could support a molecule-level reassessment, but they would not create a clinical outcome or safety record for the blend.

tesa+ipa blend · tier A

the GH-axis pairing built on the one GHRH leg that carries an FDA approval, tesamorelin, run alongside ipamorelin. the components are strong, the use is off-label, and the blend itself has no trial.

tier rationale

A-tier reflects unusually strong component evidence: tesamorelin is the only GHRH analog with a full FDA approval and a phase 3 package, and ipamorelin has the cleanest GHRP selectivity data in its class. Not S, because that approval covers HIV-associated visceral fat rather than this blend or this GH-axis use, because using tesamorelin this way is off-label, and because no fixed-dose tesa+ipa outcome trial exists. The pharmacology is coherent and the components are well-documented; the combined product is still clinic practice rather than trial-grade evidence.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.